Institution
University of South Florida
Education•Tampa, Florida, United States•
About: University of South Florida is a education organization based out in Tampa, Florida, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 34231 authors who have published 72644 publications receiving 2538044 citations. The organization is also known as: USF.
Topics: Population, Poison control, Cancer, Health care, Mental health
Papers published on a yearly basis
Papers
More filters
•
Memorial Sloan Kettering Cancer Center1, Stanford University2, Ohio State University3, Roswell Park Cancer Institute4, Washington University in St. Louis5, University of Alabama at Birmingham6, University of Utah7, Duke University8, Harvard University9, Brigham and Women's Hospital10, City of Hope National Medical Center11, Fred Hutchinson Cancer Research Center12, Fox Chase Cancer Center13, Vanderbilt University14, University of South Florida15, University of Nebraska–Lincoln16
TL;DR: In this article, different subtypes of non-Hodgkin's lymphoma (NHL) were compared using histological and immunohistochemical methods, including the normal lymph node structure and function.
Abstract: Part 1 Lymphomagenesis: Lymphocyte differentiation Adult T-cell leukaemia/Lymphoma - a model of retrovirus-induced lymphomagenesis Burkitt's lymphoma and Epstein-Barr virus-associated lymphoid malignancies - models for lymphomagenesis T(14 18) translocation. Part 2 Methods: Histological and immunohistochemical methods Genotype. Part 3 Nodal Non-Hodgkin's Lymphomas: The normal lymph node - structure and function Histological classification Staging of NHLs Analytical study of the different subtypes of NHLs - clinical, histological and immunohistochemical aspects NHLs in childhood NHLs associated with HIV infection. Part 4 Extra-Nodal Non-Hodgkin's lymphomas: Malignant lymphomas of mucosa-associated lymphoid tissues Primary gastrointestinal NHLs Pathology of gastro-intestinal NHLs Cutaneous lymphomas NHLs of the Mediastinum NHLs of the lung Bone marrow involvement Blood involvement in chronic (mature) B & T lymphoproliferative syndromes Liver involvement Spleen involvement Extra-cranial head-and-neck NHLs Central nervous system involvement NHLs of bone Urogenital localizations. Part 5 Treatment of Non-Hodgkin's Lymphomas: Methodology and problems in the comparison of results Treatment of lowgrade NHLs The role of radiation therapy Treatment of aggressive lymphomas (intermediate and highgrade) Intensive chemoradiotherapy and bone-marrow transplantation Salvage therapy after failure Treatment of NHLs in childhood.
465 citations
•
University of Massachusetts Boston1, Brown University2, University of Texas MD Anderson Cancer Center3, University of California, San Diego4, University of South Florida5, University of Massachusetts Medical School6, Loyola University Chicago7, University of Florida8, Rush University Medical Center9, Dartmouth College10
TL;DR: In patients with solid tumor neoplastic meningitis, DepoCyt produced a response rate comparable to that of methotrexate and significantly increased the time to neurological progression while offering the benefit of a less demanding dose schedule.
Abstract: Standard treatment for neoplastic meningitis requires frequent intrathecal (IT) injections of chemotherapy and is only modestly effective. DepoCyt is a sustained-release formulation of cytarabine that maintains cytotoxic concentrations of the drug in the cerebrospinal fluid (CSF) for more than 14 days after a single 50-mg injection. We conducted a randomized, controlled trial of DepoCyt versus methotrexate in patients with solid tumor neoplastic meningitis. Sixty-one patients with histologically proven cancer and positive CSF cytologies were randomized to receive IT DepoCyt (31 patients) or IT methotrexate (30 patients). Patients received up to six 50-mg doses of DepoCyt or up to sixteen 10-mg doses of methotrexate over 3 months. Treatment arms were well balanced with respect to demographic and disease-related characteristics. Responses occurred in 26% of DepoCyt-treated and 20% of methotrexate-treated patients (P = 0.76). Median survival was 105 days in the DepoCyt arm and 78 days in the methotrexate arm (log-rank P = 0.15). The DepoCyt group experienced a greater median time to neurological progression (58 versus 30 days; log-rank P = 0.007) and longer neoplastic meningitis-specific survival (log-rank P = 0.074; median meningitis-specific survival, 343 versus 98 days). Factors predictive of longer progression-free survival included absence of visible central nervous system disease on neuroimaging studies (P<0.001), longer pretreatment duration of CSF disease (P<0.001), history of intraparenchymal tumor (P<0.001), and treatment with DepoCyt (P = 0.002). The frequency and grade of adverse events were comparable between treatment arms. In patients with solid tumor neoplastic meningitis, DepoCyt produced a response rate comparable to that of methotrexate and significantly increased the time to neurological progression while offering the benefit of a less demanding dose schedule.
465 citations
••
24 Jun 2008TL;DR: In this article, the Simple Storage Service (S3), a commodity-priced storage utility, is evaluated from a cost, availability, and performance perspective for large-scale science projects.
Abstract: Amazon.com has introduced the Simple Storage Service (S3), a commodity-priced storage utility. S3 aims to provide storage as a low-cost, highly available service, with a simple 'pay-as-you-go' charging model. This article makes three contributions. First, we evaluate S3's ability to provide storage support to large-scale science projects from a cost, availability, and performance perspective. Second, we identify a set of additional functionalities that storage services targeting data-intensive science applications should support. Third, we propose unbundling the success metrics for storage utility performance as a solution, to reduce storage costs.
464 citations
••
TL;DR: The relation between work-family conflict and job satisfaction was examined using a six-dimensional measure of WFC and both global and summed facet (i.e., composite) measures of job satisfaction.
464 citations
••
TL;DR: Better identification of endotypes might permit individualization of therapy that can be targeted against the pathophysiologic processes of a patient's endotype, with potential for more effective treatment and better patient outcomes.
Abstract: Chronic rhinosinusitis (CRS) is a complex disease consisting of several disease variants with different underlying pathophysiologies. Limited knowledge of the mechanisms of these disease subgroups is possibly the greatest obstacle in understanding the causes of CRS and improving treatment. It is generally agreed that there are clinically relevant CRS phenotypes defined by an observable characteristic or trait, such as the presence or absence of nasal polyps. Defining the phenotype of the patient is useful in making therapeutic decisions. However, clinical phenotypes do not provide full insight into all underlying cellular and molecular pathophysiologic mechanisms of CRS. Recognition of the heterogeneity of CRS has promoted the concept that CRS consists of multiple groups of biological subtypes, or "endotypes," which are defined by distinct pathophysiologic mechanisms that might be identified by corresponding biomarkers. Different CRS endotypes can be characterized by differences in responsiveness to different treatments, including topical intranasal corticosteroids and biological agents, such as anti-IL-5 and anti-IgE mAb, and can be based on different biomarkers that are linked to underlying mechanisms. CRS has been regarded as a single disease entity in clinical and genetic studies in the past, which can explain the failure to identify consistent genetic and environmental correlations. In addition, better identification of endotypes might permit individualization of therapy that can be targeted against the pathophysiologic processes of a patient's endotype, with potential for more effective treatment and better patient outcomes.
464 citations
Authors
Showing all 34549 results
Name | H-index | Papers | Citations |
---|---|---|---|
David J. Hunter | 213 | 1836 | 207050 |
Aaron R. Folsom | 181 | 1118 | 134044 |
John Hardy | 177 | 1178 | 171694 |
David Cella | 156 | 1258 | 106402 |
Arul M. Chinnaiyan | 154 | 723 | 109538 |
Andrew D. Hamilton | 151 | 1334 | 105439 |
Charles B. Nemeroff | 149 | 979 | 90426 |
C. Ronald Kahn | 144 | 525 | 79809 |
Alexander Belyaev | 142 | 1895 | 100796 |
Tasuku Honjo | 141 | 712 | 88428 |
Weihong Tan | 140 | 892 | 67151 |
Alison Goate | 136 | 721 | 85846 |
Peter Kraft | 135 | 821 | 82116 |
Xiaodong Wang | 135 | 1573 | 117552 |
Lars Klareskog | 131 | 697 | 63281 |